Your Cart is Empty
SWISS QUALITY SINCE 2013
CUSTOMERS IN 40+ COUNTRIES
5-STARS ON TRUSTPILOT
GLOBAL DELIVERY
SWISS QUALITY SINCE 2013
CUSTOMERS IN 40+ COUNTRIES
5-STARS ON TRUSTPILOT
GLOBAL DELIVERY
Here you will find the latest news about our company.
We have established Formula Swiss UK Ltd. as a subsidiary in North Yorkshire in the U.K. and have applied for local VAT registration.
Having a local presence in the U.K. will have many positive implications for our customers and wholesale partners.
From end of April, our customers in the U.K. will no longer have to deal with the Brexit-implications. The local custom clearing will be much faster going forward, and our customers will no longer have to pay any kind of fees, duties or VAT when receiving our products.
We will pay local VAT and import duties for all deliveries to the U.K.
We have notified the Office for Product Safety and Standards (OPSS) about all our cosmetic CBD products available to Great Britain consumers.
All our product information is available for the British authorities in the Cosmetic Product Notification Portal' or 'SCNP', a similar system as the European Union's CPNP system.
We have updated our About Us-page with more information about our company, mission, production, quality, studies.
You can access the page here.
Feel free to comment and send us feedback.
It was time to again count the number of countries, where our customers live.
Last time we updated the list back in 2019, we had 35 countries. Now the list have grown to 58 countries in total.
With the internet and global shipping via UPS our customers can now order from anywhere in the World and have their order delivered within a couple of days. UPS delivers within 48 days to San Diego, New York, Tokyo, Bangkok and within a couple of days inside Europe.
Australia
Austria
Bahamas
Belgium
Brazil
Bulgaria
Canada
Chile
Croatia
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Greenland
Guinea
Hong Kong
Hungary
Iceland
India
Ireland
Israel
Italy
Japan
Laos
Latvia
Lebanon
Liechtenstein
Luxembourg
Lithuania
Malta
Mexico
Monaco
Morocco
Netherlands
New Zealand
Norway
Poland
Romania
Portugal
Russia
Serbia
Singapore
Slovakia
Slovenia
Spain
Sweden
Switzerland
Taiwan
Thailand
Turkey
Ukraine
United Arab Emirates
United Kingdom
United States
Sleep disorders and insufficient sleep have a high prevalence worldwide and numbers are increasing each year costing society a fortune.
The Netherlands shows a point prevalence of 32.1% in 2016. Symptoms include poor sleep quality, non-restorative sleep, early awakenings, and difficulty initiating and maintaining sleep. More importantly but barely recognized by health professionals and the general public are the health hazards people risk by not getting enough good quality sleep.
There is an increased risk for diabetes, obesity, hypertension, coronary heart disease (CHD), stroke, mental disorders, including anxiety and depression, but also dementia suppressed immune system and death due to cancer, stroke and CHD. A relevant study carried out by RAND Corporation calculated that sleep deprivation costs 1.56-1.86% of GDP yearly in Germany and United Kingdom respectively, accounting for 13–15 Billion Euro per year in The Netherlands and 50-60 Billion Euro per year in Germany and The United Kingdom.
Researchers, attached to the University of Groningen in the Netherlands, believe that the promising values of full spectrum cannabidiol (CBD) and cannabinol (CBN) products can have calming neuroprotective and sedative effects on the central nervous system, and thus may be safe alternatives for sleep problems.
The Dutch researchers are planning a large double-blinded, randomized placebo-controlled crossover trial study on more than 300 people in The Netherlands using legal cannabis products from the Swiss cannabis producer, Formula Swiss AG, on patients with irritable bowel syndrome (IBS) and musculoskeletal pain due rheumatoid arthritis (RA).
This study will give insight into the potential benefit of cannabinoids on sleep by influencing the underlying disease mechanisms, which also positively affects disease symptoms and thus quality of life. An individual that sleeps on average less than six hours per night has a 13 per cent higher mortality risk than someone sleeping between seven and nine hours. An individual sleeping between six to seven hours per day still has a seven per cent higher mortality risk.
Improving the total amount of sleep and sleep quality will not only reduce a long list of health problems, but also improve the quality of life, because good sleep is one of the cornerstones of good health.
Further analysis showed that if total sleep time of people, who currently sleep less than 6 hours per night, would be augmented to 6-7 hours, costs would drop to 1.10% - 1.60% GDP thereby saving society 2.17–3.85 Billion Euro per year.
Addressing sleep deprivation will reduce health and work-related costs dramatically.
Contact for more information:
Drs. I. Niedlich den Herder Pathologist, medical manager, researcher plantbasedera@gmail.com (+31) 646740912
Robin Roy Krigslund-Hansen CEO Formula Swiss AG, Blegistrasse 13, 6340 Baar, Switzerland www.formulaswiss.com (+41) 78 932 8584, robin@formulaswiss.com
Today, we have just launched two new very strong CBD oils in our webshop.
Full-spectrum CBD oil with 3.000 mg. CBD in MCT oil with natural flavour and with strawberry flavour.
The new CBD oils are available as 6 and 10 pcs. bundles as well.
As we promised you, we are launching a lot of new CBD products this year.
Today, we would like to present to you our new product line of 18 new, organic CBD skincare products made from the very best certified ingredients available.
We spent more than nine months developing all these products and are very satisfied with the results. We hope you and will love them as well.
All CBD skincare products are certified organic, vegan and hand-made. They are also officially registered in EU´s cosmetics database (CPNP).
We use premium packaging like white-glass bottles instead of plastic containers and packaging, when possible, and only use packaging material from sustainable wood production certified in Switzerland.
The new CBD skincare products contain 3 to 6 times more CBD than our previous CBD balms and creams, but are being offered at the same prices as before.
The products are now ready for immediate delivery from our warehouse.
As from today, we are have started a promotion offering 17-20% discount on all our CBG, CBN, CBC and Pet CBD oils bundles.
This limited-time promotion can be combined with existing promotions on our website, including subscription discounts.
We would like to share some exciting news with you.
Today, we are launching three, new CBD oils with a decarboxylation of just 60%, which ensures that the CBD oil keeps a high level of natural CBDa.
The products are available in our webshop.
CBDa stands for cannabidiolic acid, and as the name suggests, this molecule is closely related to CBD. In fact, scientists consider CBDa to be the parent molecule of CBD as it is converted to CBD through the process of decarboxylation (often through heating).
CBDa is what is known as a carboxylic acid, meaning that its structure contains a carboxyl group comprising one carbon, one hydrogen, and two oxygen atoms, commonly expressed as COOH. When you expose this molecule to high temperatures, this group breaks up to form carbon dioxide and hydrogen. What you are left with is cannabidiol (CBD).
Although to some extent this reaction happens naturally over time, the process is extremely slow. However, when you smoke or vape cannabis, you speed up the process greatly.
One of the conditions for which CBDA is offering hope is cancer, specifically breast cancer. Studies have shown that CBDa has the potential to suppress breast cancer cells and inhibit them from spreading throughout the body, a process known as metastasis.
The researchers found that exposing cancer cells to CBDa for just 48 hours downregulated the expression of an enzyme called cyclooxygenase-2 (COX-2), which is part of the inflammatory process and may play a role in as many as 40% of cases of invasive breast cancer. CBDa also appeared to influence a gene called SHARP1 (also known as BHLHE41), which has the action of inhibiting breast cancer metastasis.
Since experts estimate metastasis to be responsible for up to 90% of the deaths related to breast cancer, this finding could prove vital in improving the prognosis for patients diagnosed with this life-threatening condition.
Since CBDa appears to inhibit COX-2, it has proven anti-inflammatory properties.
Many conventional anti-inflammatory drugs work by inhibiting COX-2, and doctors commonly prescribe them in the treatment of painful conditions such as arthritis.
A study found that CBDa effectively relieved toxin and motion-induced vomiting in shrews, and reduced nausea in rats. Most significantly, these scientists suggest that CBDa could reduce nausea and vomiting even more effectively than CBD.
It appears that these potent effects are a result of CBDa enhancing the activation of 5-HT1A receptors. These receptors are designed to bind with the neurotransmitter serotonin and are prevalent in the digestive system.
More research is definitely necessary to establish the effects of CBDA on nausea and vomiting in humans. However, if proven, this treatment could offer a much needed relief to patients suffering from the side effects of chemotherapy as well as nausea related to other conditions.
There is little evidence currently available to support this use of CBDa, but some have suggested that this compound could be useful in the treatment of stress and anxiety in humans, due to many similarities with CBD.
In this article we will explain, why all CBD products for oral consumption - including CBD capsules, CBD gummies, CBD oils for oral consumption - and all other CBD edibles are currently considered illegal products in all EU Member States.
We will also give our opinion on, why our company and many other stakeholders in Europe believe the legal interpretation and enforcement of the laws inside the European Union are wrong as well as why the legal situation is expected to change in the coming years.
The first Novel Food regulation was introduced back in 1997 by Regulation (EU) 258/97 with the aim of establishing a food safety mechanism to control newly developed, synthetic or genetically produced food and food supplements. An updated version of the regulation came into force on January 1st, 2018 (Regulation (EU) 2015/2283).
According to art. 3, ‘novel food’ is defined as:
“any food that was not used for human consumption to a significant degree within the Union before May 15,1997”.
If a food is considered novel, the implications are that it must be authorised by the EU Commission and undergo a pre-market safety assessment by the European Food Safety Authority (EFSA), before it can be legally marketed in the EU.
The Novel Food Catalogue serves as a non-legally binding orientation on whether a product (of animal and plant origin, as well as other substances) will need an authorisation under the Novel Food Regulation. The Novel Food Catalogue reflects the opinion of the Member States. As such, references to the Novel Food Catalogue cannot be used restrict cannabis products in the European Union, nor in Switzerland, but nevertheless it is happening on a daily basis.
Until the end of 2018, extracts of cannabidiol were considered novel only if the levels of cannabidiol were “higher than the CBD levels in the source Cannabis sativa L.”. In other words, naturally derived cannabidiol was allowed, if it was in 2-5% concentration, which is the natural level of CBD in most EU-approved hemp strains, whereas stronger concentrations were considered novel and thus illegal.
The EU Standing Committee already decided in December 1997 and the Commission confirmed to the European hemp industry in writing in the beginning of 1998 literally:
“it was decided that foods containing parts of the hemp plant do not fall under the scope of the regulations EC 258/97” and also “that hemp flowers ... are considered to be food ingredients” (e. g. used for the production of beer-like beverages)”.
Obviously, hemp flowers and leaves being parts of the hemp plant, were not considered to be Novel Food.
In January 2019, EU Member States’ representatives updated the Novel Food Catalogue entries for “Cannabis sativa L.” and “Cannabinoids”. These updates are demonstrably incorrect, based on logic and historical facts, as organizations like European International Hemp Association (EIHA) and many others stakeholders repeatedly explained to Member States and the European Commission.
The new entry for “Cannabis sativa L.” does no longer mention hemp leaves and flowers. From this alone, it is obvious that the latest changes, which seem to be hastily written, concerning the entries in the Novel Food catalogue are incorrect. Moreover, the traditionally produced hemp extracts are now also missing, although extraction is considered as a traditional and conventional method of food processing.
In the new entry for “Cannabinoids” extracts with a naturally occurring level of cannabinoids are now excluded, although they were mentioned in the previous entry formulation. Such products were already on the market and consumed before 1997 to a significant degree.
CBD extracts can be aqueous extracts (e.g. “for beer-like beverages”), extracts by pressing, extracts based on fat extraction (“defatted hemp seed”) or extracts produced by traditional extraction agents.
Since 2009, the EU directive 2009/32/EC clearly states that traditional extraction agents, such as ethanol (alcohol) or CO2 (carbon dioxide), must be permitted by Member States in the production of foodstuffs or food ingredients.
In simple terms, this means that when a food or food ingredient is processed through a traditional production method of extraction by means of the extraction agents listed and authorized in the Directive, it remains a food or food ingredient and is not considered a "novel food" product (cf. Art. 2(1), 2nd subparagraph of the Directive).
The subsequent update of the Novel Food Regulation (2015/2283) can therefore, taking into account this already existing Directive 2009/32/EC, only mean novel extraction agents and "new extracts", but not extracts obtained and produced by the traditional extraction agents already regulated.
Several cannabis industry organizations in Europe have already shared substantial evidences with the European Commission proving that hemp flowers, leaves and extracts have been consumed as food for centuries and that the so-called "low-THC" varieties, defined as industrial hemp, have historically always contained cannabidiol (CBD). Particularly in these industrial hemp varieties - including those that were already listed in the EU catalogue of varieties long before 1997 - the respective content of CBD in relation to THC is very high compared to "high-THC" cannabis varieties.
The general industry position shared by our company as active members of and strong supporters of EIHA as well as legal experts is that hemp leaves and flowers as well as such hemp extracts from industrial hemp, with the natural content of cannabinoids, (i.e. those that are not enriched with CBD isolate and crystals) are traditional foods and do not fall under the scope of the Novel Food Regulation. This position is perfectly in line with the Novel Food Catalogue entries’ formulations in place until January 2019.
Follow our blog to stay updated on the legal situation of hemp and cannabis in Europe.
We are currently working on a new version of our website with the objective of building a new design and structure to better accommodate many new CBD products and product categories.
While the website is being worked on, some parts of the website might not be working as usual and some links might be broken.
We sincerely apologize for any inconvenience caused by the work on our website and will do our best to finish the work in approximately 10 days from now.
Today, we would like to share some exciting news with you.
We are launching three, new full-spectrum CBD oils with a high concentration of the most popular and effective cannabinoids - CBG, CBN and CBC.
The products will be available for ordering next week.
The 10 ml bottle contains 1% CBG (100 mg), 3% CBD (300 mg) and a full spectrum of cannabinoids with less than 0.2% THC diluted in organic MCT oil.
Cannabigerol is the most well-known cannabinoid after CBD and THC - and very important one. In the hemp plant both THC and CBD actually originates from CBG.
Every cannabis grower tries to develop hemp strains with higher amounts of CBG due to the many benefits of the cannabinoid.
CBG is a very powerful vasodilator and has many neuroprotective benefits. As there are endocannabinoid receptors located within the eye structure, it is believed that CBG is one of the best cannabinoids for supporting glaucoma by decreasing the intraocular pressure in the eyes.
CBG may help against inflammation, colon disorders, irritable bowel, bladder dysfunctions, thyroid issues, Huntingtons Disease and inhibits abnormal cell growth etc.
Many also believe that CBG can block the receptors in the cancer cells, thus inhibiting growth of cancer cells. Read more about CBG.
The 10 ml bottle contains 1% CBN (100 mg), 3% CBD (300 mg) and a full spectrum of cannabinoids with less than 0.2% THC diluted in organic MCT oil.
In short this cannabinoid is popular for stimulating appetite, servere pain, regulate sleep, CNS disorders, neuro-inflammatory disorders, firbrosis etc. Research has shown that it is also antibacterial, anti-inflammatory and sedative.
We just published a very detailed article about CBN that we recommend you read.
The 10 ml bottle contains 1% CBN (100 mg), 4% CBD (400 mg) and a full spectrum of cannabinoids with less than 0.2% THC diluted in organic MCT oil.
Although CBC has not been proven to have a direct pain-relieving effect on its own, the cannabinoid has another characteristic: its comprehensive pharmacological properties.
Scientists tested the cannabinoid and its substances for their possible anti-inflammatory and antibacterial effects in the early 1980s. CBC can act as an antibiotic against fungal infections and can be used as an antibiotic against bacteria that no longer respond to conventional antibiotics due to increasing resistance.
CBC may help support gastrointestinal, postoperative pain, Crohn’s Disease and gut health.
We also just published a very detailed article about CBC that we recommend you read as well.
We continuously want to improve the customer experience with our products.
Over the last three years, we have developed more than 150 different CBD oil products and continue to come up with new formulations to cover the increasing demand for organic CBD oils.
We have been working closely with our supplier of pipettes for our CBD oils to improve the quality and value for our customers.
The new version of the pipette is even more durable and has been air pressured to not leak under any circumstances during transport on road, sea or air in pressurised and non-pressurised cargo rooms etc.
It has built-in child protection, but it is still possible to open for people with little power in their hands.
Today, we have placed an order of 1.2 million pipettes with the millilitres scale and our brand printed on the pipettes to be delivered by end of May. Very soon all our products will be with the new pipette design.
We look forward to hearing your opinion on the new pipette.
Since the beginning of March, we have been working on sourcing many million hand sanitisers and protective masks for hospitals, governments and healthcare workers all over Europe in partnership with Swiss medical supplies companies, pharmaceutical companies and producers of medical supplies.
Our strategic partnership allow us to source personal protective equipment (PPE) from trusted suppliers with CE- and FDA certification and test certification on the productions at reasonable prices. As you have probably heard in the media already, many new factories in China, Taiwan and India have started to produce personal protective equipment with fake product licenses under conditions not suitable for medical equipment.
We have temporarily setup a joint unit in Switzerland to check the quality of all incoming products to avoid issues with product quality, quantity, damage during transport and to repack into packaging translated for the target country to ensure the receiver understands the correct use of the protective equipment.
Now that the healthcare workers are well covered with personal protective equipment, we have decided to offer the products to private individuals through our webshops.
It is important in the weeks and months to come when societies start to gradually open up that everyone have access to quality personal protective equipment at affordable prices.
We have a stock of millions of different certified and licensed protective masks and more than 50.000 Liters of hand sanitisers available in our warehouse. Our prices are the lowest prices in Switzerland and we can deliver fast by UPS to any country in the World.
Please notice that the hand sanitiser produced in the United Kingdom has been effectively tested and certified against CovID-19 and other viruses.
You can see the selection of PPE products here.
We will add more products to the webshops as we receive them.
If you want to purchase a large quantity of products for your family, company, organisations or for donations, please contact us at wholesale@formulaswiss.com and inform us about the detailed purpose of the order and our team will evaluate it.
We do not allow anyone to resell our products and take financially advantage of the CovID-19 situation by pricing up our products, repacking them etc.
Our products are developed for private and non-medical usage only.
The Coronavirus pandemic has caused a global explosion in demand for medical supplies and in particular for medical-grade hand sanitisers for hospitals, clinics and private households.
The global supply is currently very limited and as such prices have gone through the roof as it is very challenging to source large quantities of ethanol for the extraction. Furthermore, the sourcing and transport of the product containers and packaging have become increasingly difficult.
As we have a large extraction capability, we have worked together with a highly respective pharmaceutical company specialising in producing medicinal products in Switzerland. We have worked closely together to produce a steril antiseptic gel with 70% ethanol.
The new hand sanitiser product is licensed in Switzerland at BAV and throughly tested with a documented effect against standard bacteria, H1N1 flu etc. We have received numerous expert opinions on the quality and effect.
We are offering this product in our webshops at very fair prices for everyone.
We kindly ask that you purchase for you and your family only. We will reject purchase orders for large quantities.
We will be donating steril antiseptic gel to hospitals in Switzerland and Romania. We will also make donations to people in need.
Thank you for your understanding.
We are proud to announce that we have signed a research collaboration with the University of Bologna and their Department of Veterinary Medical Sciences for a range of studies for the effect of cannabidiol (CBD) in animals.
Professor Roberto Chiocchetti DVM, PhD. and his team from Department of Veterinary Medical Science are very well respected for their extensive veterinary medical science research and have published more than 60 publications to date.
Formula Swiss AG was founded in 2013 and now produce more than one hundred different CBD products in Switzerland for clients in 38 countries. Formula Swiss will support the research teams with products, formulations, knowledge and research funding.
With the collaboration between Professor Roberto Chiocchetti´s team of experts researchers and Formula Swiss in Switzerland, we will gain valuable knowledge about the reactions and results of cannabidiol (CBD) in animals to the benefit of not just the animals, but everyone interested in learning more about the effect of cannabinoids for animals.
The first study "Localization of cannabinoid and cannabinoid related receptors in the cat gastrointestinal tract" is available here.
Cannabinoid receptors showed a wide distribution in the feline gastrointestinal tract layers. Although not yet confirmed/supported by functional evidences, the present research might represent an anatomical substrate potentially useful to support, in feline species, the therapeutic use of cannabinoids during gastrointestinal inflammatory diseases.
The next study will be CBD for horses followed by several other studies of the effect of CBD for different animals.
Dear customers
Even though the ban on events in Switzerland is only valid until the end of April 2020 due to the coronavirus, CannaTrade will definitely not take place in May 2020. It would be irresponsible towards you as visitors and towards the exhibitors.
The already announced possible postponement dates (end of August, beginning of October) have been checked intensively for advantages and disadvantages and the organizers have come to the following conclusion: The CannaTrade will be postponed with a heavy heart by one year, to 28th-30th May 2021.
Under cannatrade.ch you will find further thoughts about this, as well as the further procedure regarding already bought tickets.
We hope to meet you next year at the CannaTrade 2021.
Dear clients,
We hope you, your family and friends are safe.
We have have been closely monitoring the ongoing COVID-19 virus situation develop from bad to worse over the past few weeks. In keeping with the guidelines from Swiss government authorities, we have taken several measures to avoid contributing to the spread of the infection within the company, as well as to avoid any production or delivery disruptions.
We can confirm that we remain fully operational during our business hours.
The Swiss government have decided to close all schools, stores and prohibit more than 5 people meeting at a time for now at least until April 4th.
All Swiss borders are closed with immediate effect for all non-urgent or private visits to Switzerland for six months.
Internally, we have taken a number of measures, technically and logistically, to deal with the emerging challenges:
Many employees have to work from home due to the change in family situation, but everyone will be working 100% and our fulfilment team will stay intact and continue to send out thousands of orders every day.
Externally, we have sourced a large supply of biomass, filters, bottles, packaging (except for our graduated pipettes), printers, toner, paper etc. to prepare for a situation like this.
We hope to stay operational for as long as possible during the Corona-virus and until the crisis subsides.
Together with our friends in the pharmaceutical industry we are also producing more than 200.000 pcs. of medical graded hand sanitisers and 500.000 pcs. of disposable protection masks under our brand and GMP-license. Starting from this week, these emergency products will be sold at prices below market level and donated to hospitals and institutions in need.
We will keep you informed of developments on our side.
We recommend anyone, who possible can, to stay inside for a couple of weeks with your loved ones. Focus on your body and mind. Try to boost your immune system with healthy food, plenty of sleep, CBD and supplements.
Kind regards,
All of us at Formula Swiss
We are very pleased to announce that this year again, we will have a booth for you at the CannaTrade 2020, which will take place in Bern from May 15th to 17th, 2020.
You will find us in hall 3 at booth 306 and we would be very pleased to meet you there in person. Feel free to contact us in advance to schedule a meeting at the conference.
At the event you will find a lot of exciting information about cannabis, hemp and CBD, an experience for young and old, which you should not miss.
You will find more information about the event on the website of the organizer - CannaTrade.ch.
We hope to see you there.
We are very pleased to inform you that we now also produce our CBD oil in a 3000 mg concentration with 30% CBD and less than 0.2% THC in either olive oil or hempseed oil.
Up to now the highest concentration of CBD in our oils was 25%. Following numerous customer requests, we have now decided to offer these additional variations as well.
The 30% CBD-oil will be available in our webshops in all flavours you are used to, such as olive oil, hempseed oil, strawberry, orange, vanilla and natural with less than 0.2% or 0.0% THC in the weeks to come.
The oil, stated to help promote sleep, ease chronic ache, and reduce strain and tension, is completely legal within the UK because it doesn’t incorporate THC - the psychoactive compound that makes you high.
Nonetheless, two thirds believe it is banned. And eight in 10 suppose the impact of taking the natural oil is similar to smoking hashish.
More than half also stated they would judge a mate or member of the family negatively in the event that they knew they took CBD. The research of two thousand adults, commissioned by a top rate CBD oil producer to rejoice the release of recent range of CBD oils, located greater than three quarters are confused by CBD. And 8 in 10 describe it - despite being totally legal - as ‘dodgy’.
As with most emerging industries, regulation is unfastened, which has caused a big deal of incorrect information and false impression surrounding CBD and tremendously lot of mis-selling.
Cannabidiol, better referred to as CBD, is a naturally occurring connection found inside the resinous flower of cannabis. While cannabis itself is an addictive drug, as soon as extracted from the plant, CBD is without a doubt a safe and non-addictive substance, with none of the side effects associated with hashish along with the sensation of being ‘high’.
A study has additionally discovered CBD is most broadly utilized by women aged 45 to 60.
67 per cent quoted to have taken or thought about taking CBD oil. At the other end of the scale, those age 25 to 30 were least likely to use CBD, with only 21 per cent willing to trying it out.
As well as general confusion around CBD, researches additionally highlighted a lack of awareness about the oil and its connection to hashish.
Two thirds are mistakenly believing its use is banned in professional sports, which is not the case. There is increasing evidence that CBD may be used to effectively treat a number of medical afflictions, inclusive pain and anxiety, and also can assist with concentration, sleep, and muscle recovery after sports activities.
Source: The Sun UKIn the coming weeks we will be very busy harvesting and drying this years production of more than 100.000 organic hemp plants. It is a large operation that require a lot of resources and experience and the entire family will be involved.
We grow many different strains of hemp plants like V1, Cannatonic, Harlequin, Strawberry and a few proprietary strains - all with amazing and popular aromas and a strong durability.
The weather in Switzerland has been ideal for the hemp plants this season. Not too warm for the greenhouses and not too windy, moist or rainy for the plant outdoors. If nothing changes in the next few weeks, we expect 2019 to yield another record output.
In the months that follows, we will start to offer sale of flowers from our different strains from greenhouse and outdoor production to our wholesale partners by the kilogram starting with a minimum purchase order of 5 kilogram of vacuum-packed flowers with a reduced THC level of less than 0.2% making them compliant in Europe and most countries.
Many have requested to buy the flowers in our webshops as well, but right now we prefer to work with our strategic partners and wholesalers in more than 35 countries.
Keep in mind that shipping hemp flowers internationally is logistically very challenging, due to the physical resemblance with marijuana plants, and thus require a lot of documentation and paperwork to pass through customs in a timely manner. It is currently not feasible to offer this service to our end customers.
This article was written by an independent and third-party author specialising in CBD, hemp and cannabis research. Any opinion, advice or recommendation expressed in the article does not reflect the opinion of Formula Swiss AG or any of our employees. We do not make any claims about any of our products and refer to our disclaimer for more information.
